Allergy and immune therapy company ALK reports better sales than predicted for the second quarter of the year. The company has also saved some money on certain expenses and on postponing certain clinical activities, so now the Danish company is upgrading its revenue and earnings guidance for full-year 2021, according to a Monday press release.
Whereas the Danish company previously forecast growth in the range of 9-12 percent measured in local currency, now it predicts to grow between 10-12 percent. This optimism is particularly due to the company's tablet sales, which have gone better than expected. Now, the company estimates tablet sales will grow 25 percent or more, whereas it previously projected growth of around 25 percent.